Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges.
Füzéry AK, Levin J, Chan MM, Chan DW. · 2013
Read Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. by Füzéry AK, Levin J, Chan MM, Chan DW. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3850675.txt.
Introduction
Anna K. Füzéry, Joshua Levin, Maria M. Chan, and Daniel W. Chan review why cancer markers stall in Clinical Proteomics in 2013. Decades of work have found many protein signs of cancer in blood and tissue. Very few reach clinic use as approved tests. The gap, they argue, is partly a knowledge gap.
Discovery teams often know little of what a clinic test must prove. A test must be exact, free of cross-talk, and steady across labs. It must also sort sick from well with known hit and miss rates, and show real use for care. The final part walks through the United States approval path for such tests as medical devices. The review aims to shape studies so more finds survive the trip to patients.
Catalog record
| CREATOR | Füzéry AK, Levin J, Chan MM, Chan DW. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges By Anna K Füzéry, Joshua Levin, Maria M Chan, Daniel W Chan Published in: Clinical proteomics DOI: 10.1186/1559-0275-10-13 ABSTRACT Tremendous efforts have been made over the past few decades to discover novel cancer biomarkers for use in clinical practice. However, a striking discrepancy exists between the effort directed toward biomarker discovery and the number of markers that make it into clinical practice. One of the confounding issues in translating a novel discovery into clinical practice is that quite often the scientists working on biomarker discovery have limited knowledge of the analytical, diagnostic, and regulatory requirements for a clinical assay. This review provides an introduction to such considerations with the aim of generating more extensive discussion for study design, assay performance, and regulatory approval in the process of translating new proteomic biomarkers from discovery into cancer diagnostics. We first describe the analytical requirements for a robust clinical biomarker assay, including concepts of precision, trueness, specificity and analytical interference, and carryover. We next introduce the clinical considerations of diagnostic accuracy, receiver operating characteristic analysis, positive and negative predictive values, and clinical utility. We finish the review by describing components of the FDA approval process for protein-based biomarkers, including classification of biomarker assays as medical devices, analytical and clinical performance requirements, and the approval process workflow. While we recognize that the road from biomarker discovery, validation, and regulatory approval to the translation into the clinical setting could be long and difficult, the reward for patients, clinicians and scientists could be rather significant. INTRODUCTION A biomarker may be defined as a molecule that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention [1]. A tumor marker, in particular, is any molecule produced by a tumor or by the host in response to a cancer cell that is objectively measured and evaluated as an indicator of cancerous processes within the body [2]. Ideally, a tumor marker is detectable only in the presence of cancer but in practice the tumor markers of today lack such exquisite specificity. Current tumor markers may be grouped into a variety of categories including proteins, glycoproteins, oncofetal antigens, hormones, receptors, genetic markers, and RNA molecules. Moreover, tumor markers may be detected in sample matrices such as serum, plasma, whole blood, urine, and tissue. Tremendous efforts have been made over the past few decades to discover novel cancer biomarkers for use in clinical practice. However, a striking discrepancy exists between the effort directed toward biomarker discovery and the number of markers that make it into clinical practice. Table 1 lists the handful of Food and Drug Administration (FDA) approved protein biomarkers in current clinical use. A number of excellent reviews, commentaries, and editorials have begun to address the source of this discrepancy and offer some insight into more successfully bridging the path from discovery to clinical diagnostics [3-9]. One of the confounding issues in translating a novel discovery into clinical practice is that quite often the scientists working on biomarker discovery have limited knowledge of the analytical, diagnostic, and regulatory requirements for a clinical assay [10]. This review provides an introduction to such considerations with the aim of generating more extensive discussion for study design, assay performance, and regulatory approval in the process of translating new proteomic biomarkers from discovery into cancer diagnostics. [Table: List of FDA-approved protein tumor markers currently used in clinical practicea] BIOMARKER DISCOVERY A formal structure to guide the process of biomarker development was proposed by Pepe and colleagues [11] and adopted by the National Cancer Institute Early Detection Research Network (EDRN). The five phases of biomarker development include (1) preclinical exploratory (2) clinical assay validation (3) retrospective longitudinal (4) prospective screening and (5) cancer control. The goal of preclinical exploratory studies is to identify one or more promising tumor markers which can then be further developed in subsequent stages of the pipeline. Currently, one of two common approaches is taken to identify a new potential tumor marker: unbiased high throughput discovery or targeted discovery. While unbiased high throughput discovery is frequently used, targeted discovery is now being promoted as the preferred approach by many groups [6,9,12]. The key advantage of the latter approach is that defining an intended use for the tumor marker at the early stages of the discovery process allows better control of the variables (other than the cancer itself) that may influence measured levels of the marker during the discovery process. Regardless of which approach is taken, a careful study design is essential to success. Some of the issues to be considered when deciding on a discovery strategy include the number of samples to analyze, inclusion/exclusion criteria for the samples, collection and handling requirements, downstream effects of sample processing, limitations of the analytical methodology(ies), appropriate statistical analysis of the acquired data, and validation of the findings in independent datasets and by independent investigators. Moreover, complete and transparent reporting of results is also necessary so that other investigators can assess the soundness of the study. For an in-depth discussion of these and other considerations, the reader is referred to several excellent published reviews [4,6,8,10,13-16]. ASSAY DEVELOPMENT: ANALYTICAL PERFORMANCE General considerations Once a promising tumor marker candidate is identified, the next step is to develop an assay with suitable analytical performance for diagnostic accuracy studies and for eventual use of the assay in routine clinical practice. One must keep in mind that proteomic technologies used in biomarker discovery are generally not transferable to clinical laboratories owing to their high complexity, relatively low throughput, and their analytical performance characteristics. Therefore, the evaluation of alternate methodologies early on is highly advisable. The OVA1 test for ovarian cancer (Vermillion, Inc), for example, was initially developed on the SELDI platform because this platform had been used to discover the five proteomic biomarkers included in the test. However, despite significant efforts the precision of the test could not be increased to clinically acceptable levels (see below for a discussion on the levels of precision that are clinically acceptable). The SELDI platform was therefore abandoned and the test was then successfully implemented using immunoassays [17]. A plethora of guidelines exist on how to establish the performance of an assay [18-28] and it is not always evident which guideline best applies to a particular assay. A general rule of thumb is that the intended use and the targeted country’s regulatory requirements should both be taken into consideration when determining the stringency of performance assessment. In order to develop an analytically robust tumor marker assay, however, at least the following parameters should be evaluated: precision, trueness, limit of detection, limit of quantitation, linearity and working range, specificity, carryover, and analyte stability. Considerations for some of these parameters will be described in the following sections; for additional information the reader is referred to the many method validation guidelines available in literature. Precision Precision refers to the closeness of agreement between a series of measurements obtained for the same sample under a specified set of conditions. Precision evaluates random error and may be identified as within-runbetween-runwithin-day, between-day, or within-laboratory [21]. Of these, within-run and within-laboratory precision are usually the first requirements for a